India — Vitamins, Minerals, Proteins, and Unconventional Dietary Specialties for Humans

← back to leaderboard

India received 482 FDA import refusals in Vitamins, Minerals, Proteins, and Unconventional Dietary Specialties for Humans between 2023-Q4 and 2026-Q3. Volume peaked at 67 in 2026-Q3, with the trend roughly flat year-on-year. The most-cited issues are unapproved, mfr inj, and dietarylbl. No trade baseline is published for this commodity from India, so no per-$1B rate is shown here.

Of these, 63 were hazard refusals and 419 were paperwork refusals.

Exporting from India? Get an email when shipments from India are refused at the US border — before your buyers ask.

Quarterly rejections, last 12 quarters

23 2023-Q4 2023-Q4: 23 23 2024-Q1 2024-Q1: 23 25 2024-Q2 2024-Q2: 25 32 2024-Q3 2024-Q3: 32 34 2024-Q4 2024-Q4: 34 46 2025-Q1 2025-Q1: 46 54 2025-Q2 2025-Q2: 54 41 2025-Q3 2025-Q3: 41 50 2025-Q4 2025-Q4: 50 52 2026-Q1 2026-Q1: 52 35 2026-Q2 2026-Q2: 35 67 2026-Q3 2026-Q3: 67

By commodity, last 156 weeks

Commodity Rejections Per $1B US imports Most-cited hazard
Supplements 303 unapproved
Herbals-Botanicals 180 unapproved

Recent rejections